Spartan RX CYP2C19 Test System
FDA 510(k) K123891 · Spartan Bioscience, Inc.
510(k) numberK123891
Submission
- Device name
- Spartan RX CYP2C19 Test System
- Applicant
- Spartan Bioscience, Inc.
Redwood Shores, CA, US - Received
- December 18, 2012
- Decision date
- August 12, 2013
- Decision
- Substantially Equivalent (SESE)
- Type
- Abbreviated 510(k)
- Summary
- 510(k) summary available from FDA
Device classification
- Product code
- NTI – Drug Metabolizing Enzyme Genotyping Systems
- Device class
- Class II (moderate risk)
- Regulation
- 21 CFR 862.3360
- Specialty
- Clinical Toxicology
Intended to identify the presence or absence of human genotypic markers encoding drug metaboizing enzymes using dna originating from clinical samples. This type of assay can be used as an aid determining treatment choice and individualizing treatment dose for therapeutics that are metabolized primarily by the specific enzyme tested by the system.
Other 510(k)s with product code NTI
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K220026 | Genomadix Cube CYP2C19 SystemNTI · Abbreviated | Genomadix, Inc. | 03/21/2023SE |
| K170492 | xTAG CYP2D6 Kit v3NTI · Special | Luminex Molecular Diagnostics, Inc. | 08/11/2017SE |
| K131565 | Xtag CYP2C19 Kit V3NTI · Traditional | Luminex Molecular Diagnostics, Inc. | 09/11/2013SE |
| K130189 | Xtag CYP2D6 Kit V3 (Including Tdas CYP2D6 Software)NTI · Traditional | Luminex Molecular Diagnostics, Inc. | 05/21/2013SE |
| K120466 | Verigene CYP2C19 Nucleic Acid Tes (2C19)NTI · Traditional | Nanosphere, Inc. | 11/06/2012SE |
| K101683 | Infiniti CYP2C19 AssayNTI · Abbreviated | Autogenomics, Incorporated | 10/25/2010SE |
| K093420 | Xtag CYP2D6 Kit V3, Model I030C0300 (96 Tests/Kit), Tdas CYP2D6 Software (2030-0254)NTI · Traditional | Luminex Molecular Diagnostics, Inc. | 08/26/2010SE |
| K051824 | Invader UGT1A1 Molecular AssayNTI · Traditional | Third Wave Technologies, Inc. | 08/18/2005SE |
| K043576 | Roche Amplichip CYP450 TestNTI · Traditional | Roche Molecular Systems, Inc. | 01/10/2005SE |
Questions and answers
When was Spartan RX CYP2C19 Test System cleared by the FDA?
Spartan RX CYP2C19 Test System (K123891) received a 510(k) decision of Substantially Equivalent on August 12, 2013, 237 days after the submission was received.
What is the product code of K123891?
The FDA product code is NTI – Drug Metabolizing Enzyme Genotyping Systems, a Class II (moderate risk) device regulated under 21 CFR 862.3360.